Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/23771
Full metadata record
DC FieldValueLanguage
dc.contributor.authorTsoumani, M. E.en
dc.contributor.authorKalantzi, K. I.en
dc.contributor.authorDimitriou, A. A.en
dc.contributor.authorNtalas, I. V.en
dc.contributor.authorGoudevenos, I. A.en
dc.contributor.authorTselepis, A. D.en
dc.date.accessioned2015-11-24T19:35:55Z-
dc.date.available2015-11-24T19:35:55Z-
dc.identifier.issn1940-1574-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/23771-
dc.rightsDefault Licence-
dc.titleAntiplatelet Efficacy of Long-Term Treatment With Clopidogrel Besylate in Patients With a History of Acute Coronary Syndrome: Comparison With Clopidogrel Hydrogen Sulfateen
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.primary10.1177/0003319711427697-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/22144668-
heal.identifier.secondaryhttp://ang.sagepub.com/content/early/2011/12/14/0003319711427697.full.pdf-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate2011-
heal.abstractThe efficacy of clopidogrel therapy in patients with an acute coronary syndrome (ACS) has been established using the clopidogrel hydrogen sulfate (CHS) formulation. We compared the antiplatelet effectiveness of long-term administration of the original CHS with a generic clopidogrel besylate (CB) salt formulation in 86 patients with a history of an ACS. At 1 month after the episode, patients receiving 75 mg/d CHS were randomized to continue with CHS (n = 41) or to switch to 75 mg/d CB (n = 45). Platelet aggregation, vasodilator-stimulated phosphoprotein (VASP) phosphorylation, P-selectin expression, and platelet-leucocyte conjugates were determined before randomization and at 6 months afterward. No difference in any platelet parameter studied was observed between the 2 groups either before randomization or after 6 months of treatment with CHS or CB. We conclude that there is no difference in the antiplatelet efficacy between CB and CHS during long-term administration in patients with a history of an ACS.en
heal.journalNameAngiologyen
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά)

Files in This Item:
File Description SizeFormat 
Tsoumani-2011-Antiplatelet Efficac.pdf358.95 kBAdobe PDFView/Open    Request a copy


This item is licensed under a Creative Commons License Creative Commons